Common Cutaneous Side Effects of Anti-cancer Agents

Zarbo, Allison; Axelson, Anna

doi:10.1007/978-3-030-18015-7_14

Cited by 2 publications

(2 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though cancer is not controllable in many cases, these agents cause undesirable side effects like anemia, appetite loss, bleeding and bruising (thrombocytopenia), hair loss, constipation, skin changes or reactions, etc. [8][9][10] . So, there is an utmost need to develop novel anticancer agents to minimize all those side effects and improve the quality of life.…”

Section: Introductionmentioning

confidence: 99%

Structural insights into styrylquinolines analogs as tubulin polymerization inhibitors: In silico Approach

Chourasia

Asati²,

Agarwal

et al. 2023

Mediterr.J.Chem.,

View full text Add to dashboard Cite

: Cancer is one of the fastest-growing epidemics that affect millions yearly. A handful of anticancer drugs are available on the market, but they produce undesirable side effects. Currently, tubulin inhibitors targeting the colchicine binding site are considered an important target due to their structural simplicity and favorable pharmacokinetics with fewer side effects. Different researchers conducted many studies to discover a novel tubulin inhibitor targeting the colchicine binding site with high safety and potency. In the present study, we performed computational analysis of 48 styrylquinolines analogs obtained from literature using different drug designing tools. The pharmacophore mapping study was conducted to identify the important pharmacophoric features essential for biological activity. Atom-based 3D-QSAR (3-dimensional quantitative structure-activity relationship) analysis was carried out to know the contribution of different atoms to model development. The generated model showed a statistically significant coefficient of determinations for the training and test sets. The best QSAR model was selected based on R2 (0.8624) and Q2 (0.6707) values. Contour plot analysis of the developed model unveiled the chemical features necessary for tubulin inhibition. A docking study was performed on potent styrylquinoline analog 9VII-f(46), which shows the highest SP docking scores (-5.494). ADME (Absorption, distribution, metabolism, and excretion) analysis provides valuable information about the drugability of newly designed compounds.

show abstract

Section: Introductionmentioning

confidence: 99%

Structural insights into styrylquinolines analogs as tubulin polymerization inhibitors: In silico Approach

Chourasia

Asati²,

Agarwal

et al. 2023

Mediterr.J.Chem.,

View full text Add to dashboard Cite

show abstract

“…Although, recently, many therapeutic options for hematologic malignancy treatment, such as tyrosine kinase inhibitors (TKIs) [ 6 , 7 ], chemotherapy and bone marrow transplantation, have significantly improved prognosis and survival of patients, some refractory (e.g., intrinsic resistance) and relapsed patients respond poorly to all current, available therapeutics [ 8 , 9 , 10 ]. Moreover, some potent cytotoxic chemotherapeutics can effectively kill cancer cells, but their severe side effects and systemic toxicity often limit their uses in broad terms due to lack of selectivity [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions

et al. 2022

View full text Add to dashboard Cite

Hematologic malignancies, including leukemia, lymphoma, myeloproliferative disorder and plasma cell neoplasia, are genetically heterogeneous and characterized by an uncontrolled proliferation of their corresponding cell lineages in the bone marrow, peripheral blood, tissues or plasma. Although there are many types of therapeutic drugs (e.g., TKIs, chemotherapy drugs) available for treatment of different malignancies, the relapse, drug resistance and severe side effects due to the lack of selectivity seriously limit their clinical application. Currently, although antibody–drug conjugates have been well established as able to target and deliver highly potent chemotherapy agents into cancer cells for the reduction of damage to healthy cells and have achieved success in leukemia treatment, they still also have shortcomings such as high cost, high immunogenicity and low stability. Aptamers are ssDNA or RNA oligonucleotides that can also precisely deliver therapeutic agents into cancer cells through specifically recognizing the membrane protein on cancer cells, which is similar to the capabilities of monoclonal antibodies. Aptamers exhibit higher binding affinity, lower immunogenicity and higher thermal stability than antibodies. Therefore, in this review we comprehensively describe recent advances in the development of aptamer–drug conjugates (ApDCs) with cytotoxic payload through chemical linkers or direct incorporation, as well as further introduce the latest promising aptamers-based therapeutic strategies such as aptamer–T cell therapy and aptamer–PROTAC, clarifying their bright application, development direction and challenges in the treatment of hematologic malignancies.

show abstract

Common Cutaneous Side Effects of Anti-cancer Agents

Cited by 2 publications

References 138 publications

Structural insights into styrylquinolines analogs as tubulin polymerization inhibitors: In silico Approach

Structural insights into styrylquinolines analogs as tubulin polymerization inhibitors: In silico Approach

The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions

Contact Info

Product

Resources

About